

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

**CHANGE OF PRINCIPAL PLACE
OF BUSINESS IN HONG KONG AND PROCESS AGENT**

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) announces that the principal place of business of the Company in Hong Kong will be changed from “Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong” to “Unit 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong” with effect from September 30, 2023.

The Board further announces that (i) Ms. CHAU Hing Ling will cease to act as an authorized representative of the Company to accept service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) as required under Rule 19.05(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from September 30, 2023; and (ii) Mr. Tim RUAN (阮添士) has been appointed as the Process Agent with effect from September 30, 2023.

By order of the Board
Ocumention Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 29, 2023

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.